Pneumococcal polysaccharide vaccination for adults: new perspectives for Europe. - Wikidata - awgldk - TriplyDB

Pneumococcal polysaccharide vaccination for adults: new perspectives for Europe.

Pneumococcal polysaccharide vaccination for adults: new perspectives for Europe.

http://www.wikidata.org/entity/Q37910264

about

Adult vaccination Pneumococcal Capsules and Their Types: Past, Present, and Future The role of vaccination in preventing pneumococcal disease in adults Effectiveness of vaccination with 23-valent pneumococcal polysaccharide vaccine in preventing hospitalization with laboratory confirmed influenza during the 2009-2010 and 2010-2011 seasons.Factors associated with pneumococcal vaccination among an urban elderly population in China Subcutaneous Immunization with Fusion Protein DnaJ-ΔA146Ply without Additional Adjuvants Induces both Humoral and Cellular Immunity against Pneumococcal Infection Partially Depending on TLR4.A case report of septic shock syndrome caused by S. pneumoniae in an immunocompromised patient despite of vaccination The management of community-acquired pneumonia in the elderly Non-invasive pneumococcal pneumonia in Portugal--serotype distribution and antimicrobial resistance Recommendations for pneumococcal immunization outside routine childhood immunization programs in Western Europe.Pneumococcal vaccines: understanding centers for disease control and prevention recommendations.Assessment of vaccine candidates for persons aged 50 and older: a review.The majority of adult pneumococcal invasive infections in Portugal are still potentially vaccine preventable in spite of significant declines of serotypes 1 and 5.A randomized clinical trial of the immunogenicity of 7-valent pneumococcal conjugate vaccine compared to 23-valent polysaccharide vaccine in frail, hospitalized elderly.Effects of Infant Pneumococcal Conjugate Vaccination on Serotype Distribution in Invasive Pneumococcal Disease among Children and Adults in Germany.Incidence of Hospitalized Pneumococcal Pneumonia among Adults in Guatemala, 2008-2012.Safety and tolerability of 13-valent pneumococcal conjugate vaccine in the elderly.The K1 capsular polysaccharide from Acinetobacter baumannii is a potential therapeutic target via passive immunization.Cost-effectiveness of polysaccharide pneumococcal vaccination in people aged 65 and above in Poland.Conjugation of polysaccharide 6B from Streptococcus pneumoniae with pneumococcal surface protein A: PspA conformation and its effect on the immune response Molecular surveillance on Streptococcus pneumoniae carriage in non-elderly adults; little evidence for pneumococcal circulation independent from the reservoir in children.Pneumococcal vaccination coverages among low-, intermediate-, and high-risk adults in Catalonia.Comparison of immunogenicity and safety of an influenza vaccine administered concomitantly with a 13-valent pneumococcal conjugate vaccine or 23-valent polysaccharide pneumococcal vaccine in the elderly.Cost-effectiveness of pneumococcal vaccines for adults in the United States.Preventing pneumococcal disease in the elderly: recent advances in vaccines and implications for clinical practice.Vaccination in the elderly: what can be recommended?Cost-effectiveness of vaccinating the elderly and at-risk adults with the 23-valent pneumococcal polysaccharide vaccine or 13-valent pneumococcal conjugate vaccine in the UK.A public health and budget impact analysis of vaccinating the elderly and at-risk adults with the 23-valent pneumococcal polysaccharide vaccine or 13-valent pneumococcal conjugate vaccine in the UK.Preventing non bacteremic pneumococcal pneumonia in older adults: historical background and considerations for choosing between PCV13 and PPV23.Pneumococcal conjugate vaccination for older adults: Reply letter to Hollingsworth et al.Contribution of host, bacterial factors and antibiotic treatment to mortality in adult patients with bacteraemic pneumococcal pneumonia.Pneumococcal infection--low awareness as a potential barrier to vaccination: results of a European study.Effectiveness and practical uses of 23-valent pneumococcal polysaccharide vaccine in healthy and special populations.Triptych of the Hermit Saints: pneumococcal polysaccharide vaccines for the elderly.A public health and budget impact analysis of vaccinating at-risk adults and the elderly against pneumococcal diseases in Germany Cost–effectiveness of vaccinating adults with the 23-valent pneumococcal polysaccharide vaccine (PPV23) in Germany

P2860

Q26824961-6AE746D1-0E9F-4F91-96FC-6F86610C6DE3 Q27006887-5D712CE1-10C1-4D38-82CB-57DE83066F85 Q28396749-A72965E7-8CD0-4594-B79D-94A0425B0118 Q30429085-22678DC3-49A4-41EC-AE12-AB77D2D8E096 Q33723367-D2B4394B-887A-45E3-8C5B-624550CA9C6A Q33785689-3289BD61-A28E-4618-A9DF-3DA69ADA5522 Q33824362-A0EEB327-51E0-403F-9AF6-FD119FFD1549 Q33915736-D27D1FC5-C3E1-4924-AC11-24851B62C4CB Q33975277-E2799048-629D-4A5B-9EAB-D1373DD48C69 Q34402444-52CD7037-CD31-43D7-818F-E85CC0D90A38 Q34425380-0C6966B5-B2A7-402A-BACC-B36ED79252F7 Q34668826-5A4E2BAE-91EF-4C0E-8E85-38425F9F3044 Q34997063-5DD28F3B-5F1B-4A2C-83C3-E66CFD0063F7 Q35156164-5CC912B1-BA0F-443A-B521-03DEE4FD82FD Q35679787-9B16ED36-6597-4189-9474-AB28BF1E50FF Q35816192-336FACF1-E65E-46C0-9930-1480C6377B4F Q35886979-B42CDBFB-69EA-48D5-A296-4CEF630E0861 Q36646787-050282F0-B3D9-4E16-BD73-ED71C3F04742 Q36864896-C2DC8EFA-17CC-49C4-9B6A-9E6BCC2B5B54 Q36911270-C371A519-43E5-434A-B86B-DDBC6C08931A Q37319027-353EB6BA-563C-4724-9955-A68D65BF0331 Q37473251-1F9D87F3-8DC3-4D61-A275-5B17B61C8590 Q37625249-368D0618-6998-4077-9743-EAEF741AC2D0 Q37729902-62A2B997-0B06-4102-BF3F-669FD346F5D0 Q38082673-B60F7D7A-3D61-4F4F-867F-C208BC401ABE Q38220158-A406880C-CE86-42F8-A17D-B481E4443489 Q41753512-DF3F8B28-E9BF-4EAF-93C9-3F120807B792 Q41755202-0FB41FB2-7ED3-4D6A-9170-D76C82700939 Q42738528-51D97A18-9A3B-4C7A-BCDE-EF1998538432 Q42923024-4AF64062-C388-4969-9D0A-6B71DEC22F29 Q43915808-0FD259DE-7C0E-4D33-907F-D2EEC04DEA97 Q44400653-50AB953E-F0CA-4F83-A99C-AB3DE8D65E8F Q48563045-AD9AB9E8-1BD7-41AE-98DA-7EEF294D1FD0 Q55267236-2DEA17C1-0B51-45ED-9D0D-76210AD1310C Q58286118-D04457C6-13A2-4FBC-8C24-9CB170CEA100 Q58286129-3D111178-5179-456D-B302-9EC05D5927B9

P2860

Pneumococcal polysaccharide vaccination for adults: new perspectives for Europe.

http://www.wikidata.org/entity/Q37910264

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Pneumococcal polysaccharide vaccination for adults: new perspectives for Europe.

@en

Pneumococcal polysaccharide vaccination for adults: new perspectives for Europe.

@nl

type

label

Pneumococcal polysaccharide vaccination for adults: new perspectives for Europe.

@en

Pneumococcal polysaccharide vaccination for adults: new perspectives for Europe.

@nl

prefLabel

Pneumococcal polysaccharide vaccination for adults: new perspectives for Europe.

@en

Pneumococcal polysaccharide vaccination for adults: new perspectives for Europe.

@nl

P1433

Q37910264-D6242F1C-149F-46D2-8A34-7376FC2CF156

P1476

Q37910264-76B13C59-2013-4FC2-BE02-62BCC9D81BC2

P2093

Q37910264-06CF86BB-0F7E-4AEE-BEEF-E76A92CE7FD8

Q37910264-3DC1FA38-DD12-419B-86FA-48B193EACDC3

Q37910264-82FA650E-9EB2-42CD-AAD2-553DFE6E2F0A

Q37910264-B3C4A0D0-13EA-4C53-8016-E7D3FB2D6244

P2860

Q37910264-0575651E-95B4-49B1-8256-B5AB2CD04624

Q37910264-0D71AB75-5F3C-492E-9ADD-2ABFFD84039E

Q37910264-0EEAB6AC-37C2-4A14-8F28-BA29A90DB22C

Q37910264-0F1B3388-FFB1-41C2-AE3E-856DE3CC6065

Q37910264-10B78AF3-A242-4CDD-A0A6-03B1A122D20C

Q37910264-12309860-2D6A-456F-A0EA-4813B127B921

Q37910264-135A8255-27AB-4028-9242-EEC090C91E68

Q37910264-14C555A2-F3AE-47BD-9921-3F0672D712CA

Q37910264-14D04FFF-EF77-45AC-B4B8-8C66589DD5D6

Q37910264-16601949-F30B-408B-9D86-BCB09E728FA1

P304

Q37910264-487AD635-E625-46B6-BF71-049750EF3801

P31

Q37910264-A05C00C8-5E6B-4867-B178-633A0B2C0771

P356

Q37910264-F8BEA2EE-3185-4DB1-BEE3-9A2F0304E9CC

P433

Q37910264-2D98E251-D0BF-4E7A-9A6E-5B7AF128D736

P478

Q37910264-B52BD13E-2C09-4229-A7B9-5516F8BEB603

P50

Q37910264-50F4401D-DA28-41C2-BE36-3DED3E2CF495

Q37910264-86DD8E41-B9B4-4E9B-892F-E7A736F8DB4B

Q37910264-FF488D29-E9C2-4664-921E-C37A9FDC27D5

P577

Q37910264-A324AA14-4592-4886-A679-C64F335C88B5

P5875

Q37910264-AD12F4C6-888E-4736-AFCD-783323F57419

P698

Q37910264-138EE4F3-6B6C-4268-9261-E76C0D6BE5AA

P921

Q37910264-049D25AC-909F-4121-8615-5E3AF78A251D

P356

P1433

Expert Review of Vaccines

P1476

Pneumococcal polysaccharide vaccination for adults: new perspectives for Europe

@en

P2093

Laurence Nicolas-Spony

http://www.w3.org/2001/XMLSchema#string

Luis Salleras

http://www.w3.org/2001/XMLSchema#string

Peter Klemets

http://www.w3.org/2001/XMLSchema#string

Sandrine I Samson

http://www.w3.org/2001/XMLSchema#string

P2860

The impact and effectiveness of pneumococcal vaccination in Scotland for those aged 65 and over during winter 2003/2004

Prior pneumococcal vaccination is associated with reduced death, complications, and length of stay among hospitalized adults with community-acquired pneumonia

Indirect effect of 7-valent pneumococcal conjugate vaccine on pneumococcal colonization among unvaccinated household members

Rapid pneumococcal evolution in response to clinical interventions

Immunogenicity and reactogenicity of pneumococcal polysaccharide and conjugate vaccines in alaska native adults 55-70 years of age.

Influenza and pneumococcal vaccination of the elderly: newer vaccines and prospects for clinical benefits at the margin.

Evolution of vaccination rates after the implementation of a free systematic pneumococcal vaccination in Catalonian older adults: 4-years follow-up

Invasive pneumococcal infections among persons with and without underlying medical conditions: implications for prevention strategies.

Initial and subsequent response to pneumococcal polysaccharide and protein-conjugate vaccines administered sequentially to adults who have recovered from pneumococcal pneumonia

Pneumococcal serotypes and mortality following invasive pneumococcal disease: a population-based cohort study

P304

1143-1167

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/ERV.11.99

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

David S. Fedson

Mark van der Linden

Agostinho J Marques

P577

2011-08-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51541138

http://www.w3.org/2001/XMLSchema#string

P698

21810065

http://www.w3.org/2001/XMLSchema#string

P921

polysaccharides